AFA.S. Filova

A.S. Filova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A.S. Filova has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alzheimer’s disease (etiology, pathogenesis, clinical presentation, diagnosis, treatment, prevention)

    by I.V. Kabachna, A.S. Filova, V.I. Kabachnyy

    Background. Alzheimerʼs disease (AD) is the leading cause of dementia, accounting for over 60% of cognitive disorders. According to WHO data, in 2024 more than 55 million people live with dementia, with around 10 million new patients added annually, a signifcant proportion of whom have AD. The number of patients is projected to double by 2050. Purpose – to summarize current data on the pathogenesis, diagnosis, and treatment of AD, with a focus on biomarkers, a staged approach, and new types of therapy targeting β-amyloid, tau protein, and efective preventive measures. Materials and Methods. During the study, recent research and international clinical guidelines, including U.S. recommendations on AD treatment, were analyzed and systematized. Results. It was established that AD develops 15–25 years before clinical manifestations and is accompanied by the accumulation of amyloid (Aβ) and phosphorylated tau protein (p-tau), which are identifed using Core 1 biomarkers (Aβ42/40, p-tau181, p-tau217) and positron emission neuroimaging. Treatment includes acetylcholinesterase inhibitors (donepezil, galantamine), memantine for moderate/severe forms, and modifed anti-Aβ antibodies (aducanumab, lecanemab), which require further evaluation of efcacy. Conclusions. AD has a long preclinical course and is currently considered incurable. Existing drugs and treatment methods are symptomatic and aimed at slowing the mechanisms of pathological protein formation and their elimination, which only delays neurodegeneration and the loss of essential life functions. In our opinion eliminating mitochondrial dysfunction, as the basis of pathological changes in neurons at all stages of AD progression, is an original and the most promising direction for the search and development of new drugs and therapeutic approaches.